Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Compared to the last administration, it’s like the dark of night and the light of day,” Alexandria Real Estate's founder said ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...